Following the release of its 2020 First Half results Kedrion S.p.A. is pleased to arrange a General Investor Call – (Credit Update).
Date & Time: Thursday September 24th @ 11.00 am UKT / 12.00 noon CET.
ITALY +39 02 805 88 11
UK +44 1 212818003
FRANCE +33 170918703
GERMANY +49 6917415713
SPAIN +34 917699497
The Company will be represented by:
Federico Latini – Global Chief Financial Officer
Peer Hansen – US General Manager
Boaglio Simone – Chief of Central Services
Pasquale Fraiese – Corporate Finance & Treasury
DOWNLOAD THE H1 2020 RESULTS PRESENTATION
For further information, please write to [email protected].
Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders. The Company operates through a fully integrated business model from the collection of plasma in its own centers in the United States and Hungary to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States. Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,700 employees and a commercial presence in approximately 100 countries worldwide. Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves. Additional information about Kedrion can be found at kedrion.com